Paris-based Sanofi is buying South San Francisco’s Amunix Pharmaceuticals in a deal topping $1.225 billion.
Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.
Alphabet Inc.’s Google and Apple Inc. announced a new system that will enable public health authorities to use smartphones to assist in contact tracing without having to build an app.
Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.
Sanofi Genzyme Executive VP Bill Sibold spoke to BioSpace about the company’s core pipeline focus, programs aimed at COVID-19, and what the future of the industry and patient care could look like in a post-COVID-19 world.
In a move aimed at boosting efficiency in drug development, Sangamo Therapeutics split the company’s research and development teams into two separate units.
This guide explores the different sources of funding available to biotech startups and their relative merits, and how you should best utilize that funding at each stage of your research.
Amgen filed a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating the company planned to lay off 149 employees effective December 31, 2019.
AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
